TABLE 1

Clinical characteristics of individuals in four studies of continuous traits and case and control subjects of the Go-DARTS type 2 diabetes study

Continuous-traits studiesType 2 diabetes case-control studies
BWHHSEFSOCHFenlandGo-DARTS*Go-DARTS (control subjects)Go-DARTS (type 2 diabetic case subjects)
n2,9711,2951,3622,6436,8605,637
Age68.8 ± 5.533.9 ± 6.044.9 ± 7.257.9 ± 11.459.3 ± 11.263.7 ± 9.3
BMI (kg/m2)27.24 ± 4.7225.52 (22.99–28.33)27.01 (4.81)26.60 (23.90–29.50)27.31 (24.71–30.51)30.76 (27.54–34.71)
Male/female (%)0/10064/3644/5647/5349.7/50.357.8/42.2
Triglycerides (mmol/L)1.57 (1.20–2.15)1.03 (0.75–1.54)1.00 (0.70–1.50)1.18 (0.86–1.71)1.33 (0.94–1.93)2.28 (1.63–3.22)
LDL cholesterol (mmol/L)4.10 (3.44–4.84)2.89 ± 0.843.39 ± 0.873.28 ± 0.883.22 ± 0.913.14 ± 0.95
HDL cholesterol (mmol/L)1.60 (1.35–2.00)1.47 ± 0.381.47 ± 0.401.60 ± 0 0.421.53 (1.26–1.85)1.16 (0.98–1.36)
Total cholesterol (mmol/L)6.60 (5.90–7.40)4.97 ± 0 0.935.37 ± 1.005.53 ± 0 0.925.62 ± 0.995.76 ± 1.18
Fasting plasma insulin (pmol/L)46.06 (30.56–63.89)44.2 (32.7–66.92)38.25 (25.80–57.10)48.61 (34.72–69.45)NANA
Fasting plasma glucose (mmol/L)5.71 ± 0.484.67 ± 0.434.85 ± 0.484.86 ± 0.47NANA
HOMA-B63.9 (49.80–82.80)107.60 (84.80–140.50)80.75 (65.00–104.00)100.50 (78.70–130.90)NANA
HOMA-IR0.83 (0.59–1.23)0.93 (0.68–1.40)0.71 (0.48–1.07)1.01 (0.64–1.51)NANA
  • Data are means ± SD for normally distributed variables and median (interquartile range) for skewed variables.

  • *Note that Go-DARTS individuals used in the continuous-traits analyses are a subset of the control subjects used in the type 2 diabetes case-control analyses.

  • †Number who met the inclusion criteria in addition to triglycerides, age, sex, and genotype for at least one SNP available except for the type 2 diabetes case-control study, in which individuals without triglyceride measures were also included.

  • ‡Age at recruitment reported.

  • NA, not applicable.